Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bevacizumab + dacarbazine in unresectable or metastatic melanoma
2005-003416-30Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and dacarbazine in melanoma, sponsored by Roche. Primary endpoint: Best tumor response at any time during therapy. Started Mar 2006; status: completed.
02
Drugs
bevacizumabdacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-003416-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003416-30.